

AIR 2017, the 7th Advancing ILD Research Educational Meeting

Barcelona, Spain 17–18 November 2017

Meeting Co-Chairs: Athol Wells, Maria Molina-Molina

Scientific Committee:

Carlo Albera, Katerina Antoniou, Jürgen Behr, Elisabeth Bendstrup, Vincent Cottin, Bruno Crestani, Jim Egan, Thomas Geiser, Andreas Günther, Michael Kreuter, Maria Molina-Molina, Venerino Poletti, Luca Richeldi, Carlos Robalo Cordeiro, Anne-Marie Russell, Simon Walsh, Athol Wells, Marlies Wijsenbeek



Friday 17th November

13:00–13:05	Introduction and overview of Roche commitment to respiratory Jean-Marc Haeusler TBD
13:05–13:10	Chairs' welcome and introduction Athol Wells, Maria Molina-Molina
13:10–13:15	iPad demonstration Agency
Session 1:	ILD: A year in review Chairs: Antje Prasse, Athol Wells
13:15–13:35	What's new in pathophysiology of fibrotic lung disease? Thomas Geiser
13:35–13:55	Have we gained new insights into the mechanism of action of antifibrotic drugs? Gisli Jenkins
13:55–14:15	What's new in ILD imaging? Simon Walsh
Session 2:	Early diagnosis and treatment of IPF
	Chair: TBD
14:15–14:35	
	Chair: TBD IPF diagnostic criteria: Imminent changes
14:15–14:35	Chair: TBD IPF diagnostic criteria: Imminent changes Athol Wells National treatment guidelines
14:15–14:35 14:35–14:55	IPF diagnostic criteria: Imminent changes Athol Wells National treatment guidelines Elisabeth Bendstrup Debate: Should all patients with IPF be treated immediately upon diagnosis? Patient organisation representative: Nicola Cassidy
14:15–14:35 14:35–14:55 14:55–15:35	IPF diagnostic criteria: Imminent changes Athol Wells National treatment guidelines Elisabeth Bendstrup Debate: Should all patients with IPF be treated immediately upon diagnosis? Patient organisation representative: Nicola Cassidy Pro: Venerino Poletti; Con: António Morais

Friday 17th November

Session 3:	Real-world patient management Chair: Carlos Robalo Cordeiro
17:00–17:20	Persisting with antifibrotic treatment – what can we learn from real-world data? Wim Wuyts
17:20–17:40	Quality of life in real-world IPF care Marlies Wijsenbeek
17:40–18:00	Comorbidities and comedications in IPF – real-world insights Michael Kreuter
18:00–18:30	Debate: Acute exacerbations and respiratory-related hospitalisation – what is more relevant for the real world? Hospitalisation: Toby Maher; Acute exacerbations: Manuela Funke
18:30–18:35	Summary and close of Day 1 Athol Wells, Maria Molina-Molina

Saturday 18th November

08:30–08:35	Welcome back to Day 2 Athol Wells, Maria Molina-Molina
Session 4:	Improving care in IPF – the patient perspective Chair: Hilario Nunes TBD
08:35–09:05	Debate: Is palliative care in IPF the same as oncology? Pro: Anne-Marie Russell; Con: Sabrina Bajwah
09:05–09:25	Strengthening the patient voice in IPF – what can we learn from PAH? Francesco Bonella
09:25–09:45	Effective patient advocacy in IPF in Europe EU-IPFF representative: Liam Galvin
09:45–10:05	Raising awareness of IPF as a rare disease – the Italian IPF charter Patient organization representative: Maria Luisa Parisi
10:05–10:30	Coffee break and group photo
Session 5:	Grand rounds in ILD
	Chairs: Sergio Harari, Dominique Valeyre TBD, Nazia Chaudhuri
10:30–12:20	Chairs: Sergio Harari, Dominique Valeyre TBD, Nazia Chaudhuri Case study reviews: Breakout session Purple Breakout session Blue Breakout session Grey
10:30–12:20 12:20–13:20	Case study reviews: Breakout session Purple Breakout session Blue
	Case study reviews: Breakout session Purple Breakout session Blue Breakout session Grey
12:20–13:20	Case study reviews: Breakout session Purple Breakout session Blue Breakout session Grey Lunch Combination therapy in IPF
12:20–13:20 Session 6:	Case study reviews: Breakout session Purple Breakout session Blue Breakout session Grey Lunch Combination therapy in IPF Chairs: Carlo Albera, Diego Castillo Pirfenidone in combination with nintedanib

Saturday 18th November

Session 7:	Advancing ILD research – future directions Chairs: Raphael Borie, Manuela Funke
14:20–14:40	Unclassifiable ILD and IPAF – diagnostic issues and treatment challenges Vincent Cottin
14:40–15:00	Categorising disease subtypes: Genetic signatures of disease Maria Molina-Molina
15:00–15:30	Debate: Is IPF an autoimmune disease? Pro: Bruno Crestani; Con: Katerina Antoniou
15:30–15:50	ILD in rheumatological conditions (RA or SSc) Christopher Denton TBD
15:50–15:55	Concluding remarks Athol Wells, Maria Molina-Molina

Faculty

Nazia Chaudhuri

Athol Wells (Co-Chair) UK Jose Ramírez Spain

Maria Molina-Molina (Co-Chair) Spain Carlos Robalo Cordeiro Portugal

Carlo Albera Italy Anne-Marie Russell UK

Katerina Antoniou Greece Nicola Sverzellati Italy

Sabrina Bajwah UK Claudia Valenzuela Spain

Jürgen Behr Germany Dominique Valeyre France

Elisabeth Bendstrup Denmark Carlo Vancheri Italy

Francesco Bonella Germany Martina Vašáková Czech Republic

Raphael Borie France Simon Walsh UK

Nicola Cassidy Ireland Marlies Wijsenbeek Netherlands

Diego Castillo Spain Wim Wuyts Belgium

Alberto Cavazza Italy

UK

Ulrich Costabel Germany

Vincent Cottin France

Bruno Crestani France

Christopher Denton UK

Sujal Desai UK

Manuela Funke Switzerland

Liam Galvin UK

Thomas Geiser Switzerland

Sergio Harari Italy

Gisli Jenkins UK

Martin Kolb Canada

Michael Kreuter Germany

Toby Maher UK

António Morais Portugal

Andrew Nicholson UK

Hilario Nunes France

Maria Luisa Parisi Italy

Venerino Poletti Italy

Antje Prasse Germany